AEGiS-FDA: FDA approval of NAT for detection of HIV-2, HIV-1 Groups O and M, and Hepatitis B and C

Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.

FDA approval of NAT for detection of HIV-2, HIV-1 Groups O and M, and Hepatitis B and C

Food and Drug Administration - December 31, 2008
Richard Klein & Kimberly Struble

On December 30, 2008, FDA approved the first nucleic acid test (NAT) that screens for the presence of two divergent types of HIV in donated blood plasma and human tissue. Nucleic acid is the term commonly used to refer to the chemical compounds that make up the genetic material in the virus. The new FDA-approved test detects nucleic acid from HIV-2 and from HIV-1 Group O. HIV-2 infections and HIV-1 Group O infections are predominantly found on the African continent. Some cases of infection with these two types of viruses have also been detected in the United States.

The new test, called cobas TaqScreen MPX Test, will allow blood donor testing laboratories to use nucleic acid technology to screen for additional the HIV strains, further assuring that donated blood and tissue are free from infection and providing better protection for patients. However, FDA is not requiring screening with the new test at this time.

In addition to HIV-2 and HIV-1 Group O, the MPX test simultaneously detects nucleic acid from the most common form of HIV, HIV-1 Group M, as well as the Hepatitis C Virus and the Hepatitis B Virus.

The MPX test is designed for use with plasma specimens from human donors of whole blood and blood components, but not for testing donated source plasma, which is collected specifically for further processing and manufacturing.

The test is also intended for screening tissue specimens obtained from living donors whose heart is still beating. It is not intended for use on specimens from donors whose heart is no longer beating.

The cobas TaqScreen MPX Test runs on the fully-automated cobas s 201 System. It is manufactured by Roche Molecular Systems Inc., Pleasanton, Calif.

Richard Klein | Office of Special Health Issues | Food and Drug Administration

Kimberly Struble | Division of Antiviral Drug Products | Food and Drug Administration
081231
FD081209

SOURCE: Food and Drug Administration (FDA).

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .